Eli Lilly and Company (NYSE:LLY) Shares Down 1.4% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s stock price fell 1.4% on Wednesday . The stock traded as low as $1,145.98 and last traded at $1,153.6920. Approximately 2,145,076 shares changed hands during trading, a decline of 29% from the average session volume of 3,016,490 shares. The stock had previously closed at $1,170.14.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO Dave Ricks said Lilly captures roughly 70% of new senior GLP-1 patients following expanded Medicare coverage, while oral GLP-1 drug Foundayo represents about one-third of new oral starts. The comments suggest strong early demand and commercial momentum. Eli Lilly CEO touts 70% share as Medicare GLP-1 program reaches 700K seniors
• Positive Sentiment: Lilly broke ground on a $6.5 billion Houston manufacturing facility that will produce active ingredients for Foundayo and other medicines. The investment should expand supply capacity and support a planned global oral GLP-1 rollout, although the benefits will take time to materialize. Lilly breaks ground in Houston
• Positive Sentiment: Analyst commentary continues to favor Lilly over Novo Nordisk, citing Lilly’s larger GLP-1 market share, expanding pipeline and stronger investor sentiment. Investor Ken Langone also said LLY could reach $2,000 within three to four years, though that is an individual opinion rather than a formal forecast. Eli Lilly Keeps Pulling Ahead
• Neutral Sentiment: Lilly expanded a Phase 4 selpercatinib safety study into India and received full FDA approval for Inluriyo in combination with Verzenio for certain advanced breast-cancer patients. These developments broaden the oncology platform but are unlikely to materially change near-term earnings.
• Negative Sentiment: Competition is intensifying. Viking Therapeutics’ VK2735 showed promising weight-loss maintenance with less frequent dosing, while Novo Nordisk’s CagriSema produced encouraging late-stage results. Although both programs remain subject to further trials or regulatory milestones, they raise concerns about Lilly’s long-term pricing power and market share. Viking’s Obesity Edge May Be Staying Power
• Negative Sentiment: The Houston project requires substantial upfront capital, and LLY trades at a high earnings multiple. Investors may therefore be taking profits or demanding clearer evidence that oral GLP-1 demand and pipeline candidates such as retatrutide can justify the valuation.

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Wednesday, September 9th. HSBC increased their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Bank of America lifted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,305.25.

Eli Lilly and Company Stock Performance

The business’s fifty day simple moving average is $1,176.84 and its 200-day simple moving average is $1,079.50. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm has a market capitalization of $1.09 trillion, a PE ratio of 38.71, a price-to-earnings-growth ratio of 1.44 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 36.54 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. State Street Corp increased its stake in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Capital World Investors lifted its holdings in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the second quarter worth about $13,522,666,000. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $12,976,634,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.